Fred Alger Management’s Fate Therapeutics FATE Stock Holding History

Fred Alger Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,837	Closed	-$1.35M	–	493
2020 Q4	$1.35M	Sell	14,837 -13,326	-47%	-$828K	﹤0.01%	351
2020 Q3	$1.13M	Sell	28,163 -5,003	-15%	-$175K	﹤0.01%	335
2020 Q2	$1.14M	Buy	33,166 +5,166	+18%	+$154K	﹤0.01%	341
2020 Q1	$622K	Sell	28,000 -20,000	-42%	-$506K	﹤0.01%	348
2019 Q4	$939K	Buy	48,000 +8,000	+20%	+$127K	﹤0.01%	348
2019 Q3	$621K	Buy	40,000 +30,000	+300%	+$575K	﹤0.01%	362
2019 Q2	$203K	Buy	+10,000	New	+$180K	﹤0.01%	400
2018 Q4	–	Sell	-11,000	Closed	-$179K	–	534
2018 Q3	$179K	Buy	+11,000	New	+$130K	﹤0.01%	389

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fred Alger Management's FATE Position: Q1 2021 in Review

Fred Alger Management sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 14,837 shares — an estimated $1.35M sold.

Fred Alger Management first reported a position in FATE in Q3 2018 and held it in 8 quarters. The position peaked at $1.35M in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

Fred Alger Management reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
Fred Alger Management sold 14,837 Fate Therapeutics shares in Q1 2021, an estimated $1.35M.
Fred Alger Management first reported a position in Fate Therapeutics in Q3 2018 and held it in 8 quarters.
Fred Alger Management's Fate Therapeutics position peaked at $1.35M in Q4 2020.
260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on Fred Alger Management's 13F filing for Q1 2021, filed 17 May 2021.